|
Mar 6
|
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expensive For A Reason? A Look At Its Intrinsic Value
|
|
Mar 4
|
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
|
|
Feb 8
|
Arrowhead Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations
|
|
Feb 8
|
ARWR: Pipeline Reprioritization to Reduce Cash Burn by up to $100 Million This Fiscal Year
|
|
Feb 7
|
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript
|
|
Feb 7
|
Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call
|
|
Feb 6
|
Arrowhead Pharmaceuticals Inc Reports Fiscal Q1 2024 Results with Strategic Focus on ...
|
|
Jan 9
|
Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 16,104 Shares
|
|
Dec 29
|
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
|
|
Dec 24
|
Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 12,000 Shares
|
|
Dec 21
|
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
|
|
Dec 20
|
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 5
|
ARWR: Updates on Plozasiran and Zodasiran at AHA 2023…
|
|
Dec 1
|
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript
|
|
Nov 30
|
Q4 2023 Arrowhead Pharmaceuticals Inc Earnings Call
|
|
Nov 29
|
Arrowhead Pharmaceuticals Inc Reports Fiscal 2023 Year-End Results
|
|
Nov 29
|
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
|
|
Nov 28
|
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
|
|
Nov 8
|
Great week for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) institutional investors after losing 17% over the previous year
|
|
Nov 6
|
Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference
|